{"nctId":"NCT02951988","briefTitle":"A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder","startDateStruct":{"date":"2016-11-13","type":"ACTUAL"},"conditions":["Depressive Disorder, Major"],"count":1304,"armGroups":[{"label":"Rapastinel 450 mg Weekly","type":"EXPERIMENTAL","interventionNames":["Drug: Rapastinel"]},{"label":"Rapastinel 450 mg Every 2 Weeks","type":"EXPERIMENTAL","interventionNames":["Drug: Rapastinel"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo-matching Rapastinel"]}],"interventions":[{"name":"Rapastinel","otherNames":[]},{"name":"Placebo-matching Rapastinel","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for MDD\n* Current major depressive episode of at least 8 weeks and not exceeding 18 months in duration at Screening\n* Have no more than partial response (\\< 50% improvement) to ongoing treatment with a protocol-allowed antidepressant\n* If female of childbearing potential, have a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test.\n\nExclusion Criteria:\n\n* DSM-5-based diagnosis of any disorder other than MDD that was the primary focus of treatment within 6 months before Screening\n* Lifetime history of meeting DSM-5 criteria for:\n* Schizophrenia spectrum or other psychotic disorder\n* Bipolar or related disorder\n* Major neurocognitive disorder\n* Neurodevelopmental disorder of greater than mild severity or of a severity that impacts the participant's ability to consent, follow study directions, or otherwise safely participate in the study\n* Dissociative disorder\n* Posttraumatic stress disorder\n* MDD with psychotic features\n* Significant suicide risk, as judged by the Investigator.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to First Relapse During the First 52 Weeks of the Double-Blind Treatment Period","description":"The time in days to first relapse is defined as the number of days from the date of randomization to the first relapse.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"232","spread":null},{"groupId":"OG001","value":"225","spread":null},{"groupId":"OG002","value":"336","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Relapse During the Entire Double-Blind Treatment Period","description":"The time in days to first relapse is defined as the number of days from the date of randomization to the first relapse.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"232","spread":null},{"groupId":"OG001","value":"225","spread":null},{"groupId":"OG002","value":"336","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Experiencing Suicidal Ideation or Suicidal Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Using 5-Point Scales","description":"On the C-SSRS, the 5 types of suicidal ideation are:\n\nType 1: \"Wish to be dead\" Type 2: Non-specific active suicidal thoughts Type 3: \"Active suicidal ideation with any methods (not plan) without intent to act\" Type 4: \"Active suicidal ideation with some intent to act, without specific plan\" Type 5: \"Active suicidal ideation with specific plan and intent\"","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":26,"n":1304},"commonTop":["Upper respiratory tract infection","Headache","Nasopharyngitis","Dysgeusia","Insomnia"]}}}